Searched for
LIPAGLYN
For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some not- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%
- Sectoral tailwinds and stronger balance sheets: 5 largecap stocks with right mix of two important ratios
- Getting back into shape? 6 Indian pharma stocks with upside potential of up to 41%The year 2024, started with a correction in nifty, but one set of stocks which were able to outperform were pharma stocks. While it might a...04 Jan, 2024, 02.09 PM IST
- Torrent, Zydus in co-marketing pact for liver disease drug SaroglitazarTorrent Pharmaceuticals and Zydus Lifesciences formed a licensing and supply pact to co-market Saroglitazar Mg, the sole approved treatment...10 Nov, 2023, 04.54 PM IST
- Zydus, Lupin enter licensing pact to market drug to treat liver diseaseZydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them. Lupin will pay Zydus upfront licensing...03 Nov, 2023, 07.38 PM IST
- Lupin, Zydus Lifesciences ink licensing, supply pact for Saroglitazar MgLupin and Zydus Lifesciences entered into a licensing and supply agreement to co-market Saroglitazar Mg, an innovative drug approved by Ind...03 Nov, 2023, 04.03 PM IST
- Zydus bets big on proprietary drugs to boost revenueSharvil Patel, managing director of Zydus Lifesciences said, half of the research and development (R&D) allocation is geared towards develo...03 Nov, 2023, 12.43 AM IST
- Zydus gets regulatory nod to market Lipaglyn in MexicoThe company has been granted marketing approval from the Mexican regulatory authority COFEPRIS to commercialise Lipaglyn in Mexico, Zydus s...10 Nov, 2017, 02.18 PM IST
- US FDA pulls up Cadila for misbranding drugThe company has been researching on the drug to treat fatty liver disease or non-alcoholic steatohepatitis apart from diabetic dyslipidemia.29 Dec, 2016, 12.15 AM IST
- Cadila Healthcare misbranded Saroglitazar, says US FDAIn a December 21 letter to the company, the US FDA has said the “broad statements” made by the company as the “world’s first” is misleading...28 Dec, 2016, 11.46 AM IST
- Zydus launches Tenglyn tablets in Indian marketDrug firm Zydus Cadila has launched its generic Tenglyn tablets belonging to new class of oral anti-diabetic treatment drugs, Gliptins, in ...20 Nov, 2015, 07.30 PM IST
- Zydus gets USFDA nod for clinical trials of Sarolitazar"USFDA has endorsed company's plan to initiate a phase II clinical trial of Saroglitazar in patients with severe hypertriglyceridemia," Zyd...18 Nov, 2015, 01.43 PM IST
- Indians face risk from unproven drugs with inadequate evidence of safety and efficacy, says medical journal"The pharmaceutical industry in India should face the same stringent regulations as elsewhere in the world, rather than continuing to allow...20 Sep, 2015, 10.09 AM IST
- Dose of bitter pills, few booster injections for pharma sectorThe pharma sector, estimated to be around Rs 1.5 lakh cr, recorded single digit growth for the first time in many years on account of deepe...29 Dec, 2013, 12.31 PM IST
- Zydus Cadila Q2 net profit up by 94%Besides Lipaglyn, the group launched 19 new products, including line extensions in India of which, four were first in India.31 Oct, 2013, 03.13 PM IST
- Zydus launches diabetes treatment drug LipaglynPharmaceutical entity Zydus group on Monday said it has launched Lipaglyn, its patented new drug for treatment of diabetes.16 Sep, 2013, 04.07 PM IST
- Expect two more novel drugs by 2020: Zydus Cadila"By 2020 we expect at least two of our 20 discovery research programmes, which are at various stages of clinical development, to become a r...09 Jun, 2013, 01.44 PM IST
- Zydus to launch first new chemical entity by desi companyCadila Healthcare on Wednesday said that its new chemical entity (NCE), Lipaglyn , has been approved by the Drug Controller General of Indi...06 Jun, 2013, 06.59 AM IST
- Zydus Cadila gets DCGI nod for launch of its NCE for diabetesCadila Healthcare today said Indian drug regulator has approved its new chemical entity, Lipaglyn to be used for treating a type of diabetes05 Jun, 2013, 02.40 PM IST
Load More
